Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients

Summary

Sitagliptin, through its effects on sensitizing alpha-cell sensitivity to glucose, can initiate counter-regulatory glucagon responses at higher glycemic thresholds, thus reducing the number of clinically apparent hypoglycemic episodes, and/or ameliorating the severity of hypoglycemic episodes in the case that they should occur. The endpoints have defined such that consequences of this hypothesis can be measured.

Timeline

Start

2018-03-21

Primary completion

2019-07-17

Completion

2019-07-17

Drugs

Indications

No indication recorded.